Navigation Links
Novel plague virulence factor identified

n the blood of mammals. There are different forms of plague in humans -- bubonic, pneumonic and septicemic -- depending on site of infection; and infections in humans are highly lethal if not immediately treated.

"Dr Aballay has developed a new model for dissecting the ways pathogens such as the plague can infect and kill their hosts," said Pamela Marino, Ph.D., scientist at the National Institute of General Medical Science. "This creative approach should improve our ability to develop new medicines to treat such diseases."

Aballay has used the C. elegans, a worm commonly found in the soil, as a model to study the virulence mechanisms of other bacteria besides plague. The worm is an ideal model for genetic studies, he said, because it takes only three days to develop from an embryo to an adult capable of reproducing. Also, scientists can easily manipulate specific genes in the worm, and in contrast to other animal models, large quantities of the worms can be grown quickly and can even be frozen and used later.

"C elegans lives in the soil, so it continually comes into contact with bacteria and other microbes," Aballay said. "It has a highly developed system for not only recognizing bacteria, but also responding to them. The ability of its innate immune system to respond appropriately to specific bacteria is very similar to that of mammals."

Aballay tested Y. pestis in his model because another research team recently reported that the bacterium killed C. elegans by creating a "biofilm" over the worm's pharynx, causing it to die of starvation. Since mammals infected with Y. pestis do not die in this manner, Aballay believed that other virulence factors were involved in infecting the worm.

"We thought that a Y. pestis strain (known as KIM5) that lacks the genes (hmsHFRS operon) required for biofilm formation could still enter the worm's digestive system and eventually kill it by using a method different from food blockage," Aball
'"/>

Source:Duke University Medical Center


Page: 1 2 3 4

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel plague virulence factor identified

(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... for Secure and Resilient Maritime Commerce (CSR) at Stevens Institute ... Stevens was named by the US Department of Homeland Security ... and was selected to lead a national research effort to ... partner with the DHS and serve as an important team ...
... Ind. - One of the most common house ant species ... smallest spaces in a forest, but the ants have found ... Grzegorz Buczkowski, a Purdue University research assistant professor of ... more complex as they move from forest to city and ...
... their wide-view neurostimulator concept a bionic eye that ... technology. The prototype bionic eye, developed by ... and unveiled today at the BVA consortium,s official launch ... of life for patients suffering from degenerative vision loss ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Bionic Vision Australia puts bionic eye in sight 2
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)... New York, NY (PRWEB) June 02, 2015 ... informative views on health care, Jack Uldrich has ... pharmaceutical firm in New York today. He will ... , Uldrich has delivered presentations to ... American Academies of Audiology and Neurology, Alcetel-Lucent/Verizon Forum ...
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, 2015 ... data from the Phase 3 multicenter study SAR3007, ... (PFS) with trabectedin (YONDELIS ® ) compared to ... leiomyosarcoma (LMS) previously treated with an anthracycline and ... the largest randomized Phase 3 study ever conducted ...
Breaking Biology Technology:R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... - Dr. Liew awarded Malaysia,s Darjah Yang Mulia ... - GeneNews Limited (TSX: GEN),a company focused on ... of diseases and personalized health management, today,announced that ... Liew,was awarded the Darjah Yang Mulia Pangkuan Negeri ...
... Imprint to Yield a Strong and ... Highly Specific Immune Response, ... ILNS) a biopharmaceutical company focused on,development of disease-modifying therapeutic agents ... announced today,that Dr. Rachel Eren, Vice President Research, will present ...
... Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced that ... than,35% over the first quarter of 2007 exceeding $1,872,000 ... same period in the previous year. Revenues for ... only,$24,374 in the first half of 2006. These significant ...
Cached Biology Technology:GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
... d1-174 GenBank Accession Number : NM_006225 ... tagged fusion protein corresponding to full length ... pH 7.4, 0.15M NaCl, 0.05% sodium azide ... Quality Assurance: routinely evaluated by immunoblot on ...
Request Info...
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: